Product Images Pregabalin

Each capsule contains 100 mg of Pregabalin and should be dispensed in USP child-resistant containers. It is manufactured by Rising Pharmaceuticals, Inc. and the usual dosage can be found in the accompanying prescribing information. It should be stored at 20°C to 25°C (68°F to 77°F) with permitted excursions between 15°C to 30°C (59°F to 86°F). The medication guide should be dispensed to each patient. The NDC number is 64980-413-10 and it is manufactured by Laurus Labs Limited in Visakhapatnam, India.*

The Rising NDC 64980-414-10 is a package of 1000 capsules containing 150mg of Pregabalin each. It is recommended to dispense the medication guide to each patient. The usual dosage should be checked in the accompanying prescribing information. The capsules should be stored between 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). The medication should be dispensed in child-resistant containers. The Rising Pharmaceuticals, Inc. manufactures it for Saddle Brook, NJ 07663, while Laurus Labs Limited also manufactures it in Visakhapatnam-531011 India.*

This is a medication called Pregabalin, which is contained in a capsule. The dosage information is not provided, and it is recommended to store the medication in a tight, child-resistant container at temperatures between 20-25°C. The medication guide should be dispensed to each patient along with their prescription. The manufacturer is Rising Pharmaceuticals, and the medication is produced by Laurus Labs Limited in India. This description does not include any mention of the uses or intended effects of Pregabalin.*

Each capsule contains 225mg of Pregabalin that should be dispensed in child-resistant containers. It is manufactured by Rising Pharmaceuticals, Inc. The dosage can be found in the accompanying prescribing information. It is suggested to store the capsules between 20°C to 25°C. The medication guide should be given to each patient by the pharmacist. The manufacturer is Laurus Labs Limited located in Visakhapatnam, India.*

This is a medication information sheet for Pregabalin capsules, manufactured by Rising Pharmaceuticals. Each capsule contains 25mg of Pregabalin and should be stored in a tight child-resistant container at 15°-30°C (59°-86°F). The medication guide should be dispensed to each patient by the pharmacist. The NDC number for this medication is 64980-410-10, and it is manufactured by Laurus Labs Limited in India.*

This is a description of a medication called Pregabalin, which comes in capsule form and contains 300mg of the active ingredient. It should be stored in a tightly-sealed, child-resistant container at a temperature between 20°C and 25°C. The medication guide for patients should be dispensed by the pharmacist. The manufacturer is Rising Pharmaceuticals, Inc. produced by Laurus Labs Limited in India. The NDC code of the medication is 64980-417-10. Dosage information should be obtained from the accompanying prescribing information.*

This is a description of a medication containing 50mg Pregabalin per capsule. The accompanying prescribing information should be consulted for dosage instructions. It should be stored at 20° to 25°C (68° to 77°F) in a tight child-resistant container. The medication guide should be dispensed to each patient, per the pharmacist's instructions. The medication is manufactured by Laurus Labs Limited in Visakhapatnam-531011 India and distributed by Rising Pharmaceuticals, Inc. in Saddle Brook, NJ 07663.*

Each capsule contains 75 mg of Pregabalin and should be dispensed in tight child-resistant containers. Dosage information can be found in the accompanying prescribing information. Store between 20°C to 25°C (68°F to 77°F) with excursions permitted between 18°C to 30°C (89°F to 86°F). The medication guide should be dispensed to each patient by the pharmacist. Available in a bottle of 1000 capsules.*

The text contains some numbers, single letters, and random characters. It's not possible to generate a useful description with this text.*

This appears to be a report or graph displaying the percent improvement in pain from a baseline for patients who took Pregabalin 160mg for three days. The graph shows that at 2 weeks, there was a 10% improvement in pain, and at 23 weeks, there was a 20% improvement in pain. The rest of the text is not available or makes no sense.*

This appears to be a chart displaying the percent of patients improved and the percent improvement in pain from baseline for various medications. The medications listed are Pregatalin, Pregabain, and Pregabalin at various dosages and frequencies. The chart also includes dates, but it is unclear what they represent without additional context.*

The text appears to be a table comparing the effectiveness of different doses of Fregabalin and Pregataiin in reducing pain. The table also includes a placebo group, and a percentage improvement in pain from baseline for each group. However, the text contains numerous errors and is difficult to interpret.*

This text appears to be a chart showing different doses of pregabalin and a placebo, along with the percentage of patients and their improvement in pain from baseline. It is not possible to determine what the chart is specifically referencing without further information.*

The text seems to be a table showing the estimated percentage of subjects without "LTR" for two different drugs, "Pregabain" and "Plcebo". The values in the table range from 0% to 20%, but there is no information about what "LTR" refers to or what kind of study or experiment this table is based on. The numbers "2 @ e & w00 12" and "160 150" seem unrelated to the rest of the text and may be artifacts of the process.*

This data displays the percentage of subjects that improved after 16 weeks on either pregabalin or placebo treatment. The percentage of subjects that improved was at 100% and it was shown along the Y-axis. The X-axis shows a range of values from 210 to 270. The percent of improvement from baseline is shown in that range. In this range, only two treatment options, pregabalin and Placebo, were assessed with the percentage of improvement they each provided. The graph displays two columns, with Pregabalin offering 280% improvement and Placebo offering 200% improvement.*